Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 2, 2024Open Access

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+cell therapy to induce fetal hemoglobin for sickle cell disease

View Full Paper
Ask AI
Bookmark
Share

Authors

VKVarun KattaSt. Jude Children's Research HospitalKOKiera O’KeefeSt. Jude Children's Research HospitalYLYichao LiSt. Jude Children's Research Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Katta et al. (2024) studied this question.

synapsesocial.com/papers/68e6bea5b6db64358763eca4https://doi.org/10.1101/2024.04.30.591737
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity2012 · 17,865 citations
  2. 2Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB ‐206 study2022 · 129 citations
  3. 3Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?1984 · 306 citations
  4. 4Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine2022 · 35 citations